Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
AKRO - Akero Therapeutics, Inc.
Market Cap 2.49B P/E - EPS this Y -27.30% Ern Qtrly Grth -
Income -204.18M Forward P/E -13.38 EPS next Y -7.60% 50D Avg Chg -4.00%
Sales - PEG 0.39 EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 6.90 EPS next 5Y -20.70% 52W High Chg -23.00%
Recommedations 1.90 Quick Ratio 24.39 Shares Outstanding 69.43M 52W Low Chg 329.00%
Insider Own 5.40% ROA -19.15% Shares Float 55.02M Beta -0.26
Inst Own 106.84% ROE -28.87% Shares Shorted/Prior 7.16M/7.19M Price 44.97
Gross Margin - Profit Margin - Avg. Volume 669,725 Target Price 45.78
Oper. Margin - Earnings Date Nov 11 Volume 722,148 Change 2.16%
Healthcare | Biotechnology | United States
About Akero Therapeutics, Inc.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics, Inc. News
12/04/24 Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
11/26/24 Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
11/15/24 Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
11/13/24 Akero Therapeutics to Present at the Jefferies London Healthcare Conference
11/12/24 Akero Therapeutics Advances in MASH Treatment Trials
11/08/24 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/02/24 Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
10/21/24 Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
10/16/24 Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin
10/15/24 Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
09/30/24 Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
09/12/24 Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
09/09/24 Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
09/04/24 Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
08/28/24 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08/09/24 Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
08/09/24 Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
08/09/24 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08/06/24 Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
07/16/24 Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Young Jonathan Chief Operating Offi.. Chief Operating Officer Dec 27 Sell 24 5,414 129,936 185,131 12/29/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Dec 27 Option 6.36 5,414 34,433 190,545 12/29/23
Yale Catriona Chief Development Of.. Chief Development Officer Dec 14 Sell 20.76 597 12,394 77,910 12/18/23
White William Richard Chief Financial Offi.. Chief Financial Officer Dec 14 Sell 20.76 611 12,684 50,354 12/18/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Dec 14 Sell 20.76 543 11,273 185,131 12/18/23
Cheng Andrew President and CEO President and CEO Dec 14 Sell 20.76 1,628 33,797 550,911 12/18/23
Rolph Timothy Chief Scientific Off.. Chief Scientific Officer Dec 14 Sell 20.76 514 10,671 182,672 12/18/23
Graham G. Walmsley Director Director Dec 08 Buy 19.83 100,000 1,983,000 800,000 12/11/23
Cheng Andrew President and CEO President and CEO Dec 07 Sell 20.02 26,978 540,100 552,539 12/11/23
Cheng Andrew President and CEO President and CEO Dec 07 Option 6.36 26,978 171,580 559,944 12/11/23
Graham G. Walmsley Director Director Nov 30 Buy 16.95 100,000 1,695,000 700,000 12/05/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Nov 17 Sell 14.6753 30,000 440,259 153,177 11/21/23
Cheng Andrew President and CEO President and CEO Oct 02 Sell 48.35 25,000 1,208,750 460,998 10/04/23
Cheng Andrew President and CEO President and CEO Oct 02 Option 6.36 25,000 159,000 485,998 10/04/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Oct 02 Sell 51.1 490 25,039 183,177 10/04/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Oct 02 Option 21.1 490 10,339 183,667 10/04/23
Cheng Andrew President and CEO President and CEO Sep 13 Sell 50.34 1,682 84,672 460,998 09/25/23
White William Richard Chief Financial Offi.. Chief Financial Officer Sep 13 Sell 50.34 632 31,815 18,468 09/25/23
Yale Catriona Chief Development Of.. Chief Development Officer Sep 13 Sell 48.85 5,617 274,390 46,010 09/25/23
Yale Catriona Chief Development Of.. Chief Development Officer Sep 13 Option 6.36 5,000 31,800 51,010 09/25/23
Rolph Timothy Chief Scientific Off.. Chief Scientific Officer Sep 13 Sell 50.34 531 26,731 150,689 09/25/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Sep 13 Sell 50.34 562 28,291 183,177 09/25/23
Cheng Andrew President and CEO President and CEO Sep 01 Sell 50 25,000 1,250,000 462,680 09/18/23
Cheng Andrew President and CEO President and CEO Sep 01 Option 6.36 25,000 159,000 487,680 09/18/23
Cheng Andrew President and CEO President and CEO Aug 30 Option 0.615 15,000 9,225 462,680 08/30/23
Yale Catriona Chief Development Of.. Chief Development Officer Aug 28 Sell 50.3 5,745 288,974 46,627 08/30/23
Yale Catriona Chief Development Of.. Chief Development Officer Aug 28 Option 6.36 5,745 36,538 52,372 08/30/23
Graham G. Walmsley Director Director Aug 08 Buy 42.0590 25,000 1,051,475 600,000 08/10/23
Graham G. Walmsley Director Director Jul 28 Buy 42.98 55,000 2,363,900 575,000 08/01/23
Cheng Andrew President and CEO President and CEO Jul 03 Sell 45.44 25,000 1,136,000 447,680 07/06/23
Cheng Andrew President and CEO President and CEO Jul 03 Option 6.36 25,000 159,000 472,680 07/06/23
Cheng Andrew President and CEO President and CEO Jun 27 Option 0.615 40,000 24,600 447,680 06/27/23
Yale Catriona Chief Development Of.. Chief Development Officer Jun 21 Sell 51.64 33,349 1,722,142 46,627 06/23/23
White William Richard Chief Financial Offi.. Chief Financial Officer Jun 20 Sell 55 20,777 1,142,735 19,100 06/22/23
White William Richard Chief Financial Offi.. Chief Financial Officer Jun 20 Option 7.01 17,500 122,675 39,877 06/22/23
Heyman Tomas J. Director Director Jun 16 Sell 54.67 26,000 1,421,420 06/21/23
Heyman Tomas J. Director Director Jun 16 Option 25.04 26,000 651,040 26,000 06/21/23
Henderson Jane Director Director Jun 16 Option 7.01 40,000 280,400 40,000 06/21/23
Henderson Jane Director Director Jun 16 Sell 54.13 40,000 2,165,200 06/21/23
Rolph Timothy Chief Scientific Off.. Chief Scientific Officer Jun 16 Sell 55.32 78,200 4,326,024 151,220 06/21/23
Rolph Timothy Chief Scientific Off.. Chief Scientific Officer Jun 16 Option 0.61 40,000 24,400 229,420 06/21/23
White William Richard Chief Financial Offi.. Chief Financial Officer Jun 13 Sell 55.16 606 33,427 22,377 06/15/23
Cheng Andrew President & CEO President & CEO Jun 13 Sell 55.16 1,613 88,973 407,680 06/15/23
Rolph Timothy Chief Scientific Off.. Chief Scientific Officer Jun 13 Sell 55.16 509 28,076 189,420 06/15/23
Young Jonathan Chief Operating Offi.. Chief Operating Officer Jun 13 Sell 55.16 538 29,676 183,739 06/15/23
Yale Catriona Chief Development Of.. Chief Development Officer Jun 13 Sell 55.16 591 32,600 79,976 06/15/23
Graham G. Walmsley Director Director Sep 19 Buy 34 520,000 17,680,000 520,000 06/15/23
Cheng Andrew President and CEO President and CEO Jun 01 Sell 45.11 25,000 1,127,750 409,293 06/05/23
Cheng Andrew President and CEO President and CEO Jun 01 Option 3.49 25,000 87,250 434,293 06/05/23
Cheng Andrew President & CEO President & CEO Apr 18 Sell 45.25 25,000 1,131,250 409,293 05/03/23